Our latest Lab Talk discusses the clinical significance of knowing the BRAF mutation status and highlights the need to optimise BRAF testing in mCRC to ensure eligible patients receive targeted therapies.
This session will explore molecular biology and the role of BRAF mutations in colorectal cancer. It will cover the heterogeneous landscape and clinical relevance of the BRAF V600E as a negative prognostic marker in mCRC. Furthermore, Prof. Fassan will deep-dive into the current diagnostic scenario, comparing and analysing different molecular techniques for optimal testing and reporting. This event will include a Q&A session at the end where you can ask Prof. Fassan your questions on this topic.
Dr. Matteo Fassan (MD, PhD) is a Professor of Pathology at Padua University and the Director of the Pathology department of the hospital Ca’ Foncello, ULSS2 Marca Trevigiana, Italy. Previously, he served as a Chief of the Molecular Pathology Diagnostics Unit of the Padua University Hospital. Furthermore, he is a coordinator of the Italian Group of the Pathologists of the Gastrointestinal Tract of the SIAPeC-IAP (GIPAD).
His research mainly focuses on the histological and molecular characterization of pre-neoplastic and neoplastic gastrointestinal pathology, with a peculiar effort on biomarker testing. On these topics, he is actively involved in clinical and translational research projects and has authored and co-authored approximately 600 peer-reviewed publications.